Gamunex 10 % inf. opl. i.v. flac. Belgium - Dutch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gamunex 10 % inf. opl. i.v. flac.

grifols deutschland gmbh - humane normale immunoglobulinen 1 g/10 ml - oplossing voor infusie - 10 % - humane normale immunoglobulinen 100 mg/ml - immunoglobulins, normal human, for intravascular adm.

Gamunex 10 % inf. opl. i.v. flac. Belgium - Dutch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gamunex 10 % inf. opl. i.v. flac.

grifols deutschland gmbh - humane normale immunoglobulinen 1 g/10 ml - oplossing voor infusie - 10 % - humane normale immunoglobulinen 100 mg/ml - immunoglobulins, normal human, for intravascular adm.

Gamunex 10 % inf. opl. i.v. flac. Belgium - Dutch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gamunex 10 % inf. opl. i.v. flac.

grifols deutschland gmbh - humane normale immunoglobulinen 1 g/10 ml - oplossing voor infusie - 10 % - humane normale immunoglobulinen 100 mg/ml - immunoglobulins, normal human, for intravascular adm.

Gamunex 10 % inf. opl. i.v. flac. Belgium - Dutch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gamunex 10 % inf. opl. i.v. flac.

grifols deutschland gmbh - humane normale immunoglobulinen 1 g/10 ml - oplossing voor infusie - 10 % - humane normale immunoglobulinen 100 mg/ml - immunoglobulins, normal human, for intravascular adm.

Gamunex 10 % inf. opl. i.v. flac. Belgium - Dutch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gamunex 10 % inf. opl. i.v. flac.

grifols deutschland gmbh - humane normale immunoglobulinen 1 g/10 ml - oplossing voor infusie - 10 % - humane normale immunoglobulinen 100 mg/ml - immunoglobulins, normal human, for intravascular adm.

Focetria European Union - Dutch - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - griepvaccins - profylaxe van influenza veroorzaakt door a (h1n1v) 2009-virus. focetria mag worden gebruikt in overeenstemming met officiële richtlijnen.

Solymbic European Union - Dutch - EMA (European Medicines Agency)

solymbic

amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - immunosuppressiva - zie sectie 4. 1 van de samenvatting van de productkenmerken in het productinformatiedocument.

FSME-IMMUN 0,25 ml Junior, suspensie voor injectie in een voorgevulde spuit Netherlands - Dutch - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

fsme-immun 0,25 ml junior, suspensie voor injectie in een voorgevulde spuit

dr. fisher farma b.v. - geÏnactiveerd tekenmeningo-encefalitis virus antigeen, neudörflstam; - suspensie voor injectie - encephalitis, tick borne, inactivated, whole virus

Cyltezo European Union - Dutch - EMA (European Medicines Agency)

cyltezo

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosuppressiva - zie sectie 4. 1 van de samenvatting van de productkenmerken in het productinformatiedocument.

Imfinzi European Union - Dutch - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - carcinoom, niet-kleincellige long - antineoplastische middelen - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).